Bringing the fundamentals into focus…
Back to Emergent BioSolutions Inc.
How Emergent BioSolutions Inc. stacks up
EBS · against 372 other Healthcare companies of similar size
Valuation
79/ 100
Near the top of its peers.
Ranked #76 of 373 · scores higher than 79% of peers
Bars: peers in each 10-point band of the valuation score33 peers with a valuation score of 70–79, including EBS · Click a bar to see the companies
Why valuation scores 79?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its free cash flow yield and EBITDA yield, which are stronger than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -54.4% vs peer median 1.5%
- more operating profit (EBITDA) for the company's total value: stronger than 97% of peers. EBITDA yield: 30.5% vs peer median 4.0%
- more free cash flow for the price paid: stronger than 98% of peers. Free cash flow yield: 26.8% vs peer median 0.0%
Metric by metric
Position: dot = EBS, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | EBS | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 356 reported | -54.4% | -0.3% | 7% | 30% | |
| EBITDA yieldHigher is better · 377 reported | 30.5% | 2.2% | 96% | 50% | |
| Free cash flow yieldHigher is better · 184 reported | 26.8% | -9.1% | 97% | 20% | |
| Book yieldHigher is better · 365 reported | 106.5% | 51.0% | 80% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around EBSScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score